Innova Captab Limited Q3 FY26 Concall Decoded: 42% Revenue Jump, Jammu Still on Training Wheels
1. Opening Hook
Just when everyone thought pharma CDMOs were catching a cold from API price deflation, Innova Captab Limited decided to pop a 42% revenue growth pill. Apparently, stabilization is the new superpower.
While some peers are busy blaming “macro headwinds,” Innova is busy adding Rs. 134 crore YoY in a single quarter. Jammu is still “nearing break-even,” yet ex-Jammu margins are flexing like they’ve hit the gym—sorry, no gym bros here.
Exports quietly climbed to 35% of mix. Branded generics sprinted 79%. CDMO kept steady at 29%. And management casually dropped a 20% growth target for FY27 like it’s routine.
But here’s the twist—Jammu isn’t contributing to EBITDA yet.
Read on. The real story starts when we strip Jammu out of the math.
2. At a Glance
Revenue up 42% YoY (Rs. 450 Cr) – Pharma slowdown? What slowdown?
“Revenue from operations surged to Rs. 450 crores with 42% year-on-year growth.” (Translation: We didn’t just grow, we surprised a few spreadsheets.)
“Branded generics surged 79% year-on-year.” (Yes, that’s not a typo. And no, it’s not all base effect 😏.)
“Exports formed 35% of Q3 revenue mix.” (Global ambitions aren’t PowerPoint slides anymore.)
“We have not contributed any PAT or EBITDA margin from the Jammu facility.” (Jammu is eating depreciation for breakfast but hasn’t started paying rent yet.)
“Ex-Jammu EBITDA margin is around 18-19%.” (So the real margin party is happening outside Jammu’s door.)
“We are hopeful of 20% plus growth next year.” (Not guidance. But also, kind of guidance.)
“API prices are now in stable territory quarter-on-quarter.” (After a year of falling knives, flat feels luxurious.)
“Jammu has potential to reach Rs. 1,400 crores at optimum capacity.” (Current run-rate ~Rs. 350 Cr annualized. Long runway ahead 🚀.)
